GLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patients

dc.contributor.authorFedor, M.
dc.contributor.authorSezer, A.
dc.date.accessioned2022-09-13T10:45:25Z
dc.date.available2022-09-13T10:45:25Z
dc.date.issued2021
dc.identifier.endpageS656en_US
dc.identifier.issn1556-0864en_US
dc.identifier.issn1556-0864en_US
dc.identifier.issue3en_US
dc.identifier.startpageS656en_US
dc.identifier.urihttp://hdl.handle.net/11727/7720
dc.identifier.volume16en_US
dc.identifier.wos000631349602018en_US
dc.language.isoengen_US
dc.relation.journalJOURNAL OF THORACIC ONCOLOGYen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectROS1(+)en_US
dc.subjectALK(+)en_US
dc.subjectlorlatiniben_US
dc.titleGLASS: Global Lorlatinib for ALK(+) and ROS1(+) Retrospective Study: Real World Data of 123 NSCLC Patientsen_US
dc.typeConference Objecten_US

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: